Skip to content

Study · Observational study · n = 29 · 2020

3 results

Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus.

Bae JH, Choi HJ, Cho KIK, Kim LK, Kwon JS, Cho YM

Diabetes & metabolism journal4 Nov 2019Cited by 32 (Europe PMC)

PMID31701698 (opens in a new tab)PMCIDPMC7188972 (opens in a new tab)DOI10.4093/dmj.2019.0018 (opens in a new tab)PepBankPUB-31701698
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyMechanism

    In obese versus lean participants with diabetes, lixisenatide reduced fusiform gyrus activation for nonfood versus high-calorie food cues (P<0.05).

    In plain wordsIn participants with diabetes, lixisenatide reduced fusiform gyrus activation more in obese than lean participants for the specified food cues.

    Peptide
    Lixisenatide
    Outcome
    DecreaseFusiform gyrus functional activation
    Study

    n = 29

    Comparator
    Lean participants with diabetes
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    P value
    < 0.05
    obese vs lean, nonfood vs high-calorie food

    Source sentences

    Summary
    Lixisenatide injection significantly reduced the functional activation of the fusiform gyrus and lateral ventricle in obese individuals with T2DM compared with that in lean individuals with T2DM (nonfood vs. high-calorie food, P<0.05).
    1 context sentence
    Summary · context
    In a randomized, single-blinded, crossover study, 15 lean and 14 obese individuals with T2DM were administered lixisenatide or normal saline subcutaneously with a 1-week washout period.
  2. 02HumanObservational studyMechanism

    In obese versus lean participants with diabetes, lixisenatide reduced lateral ventricle activation for nonfood versus high-calorie food cues (P<0.05).

    In plain wordsIn participants with diabetes, lixisenatide reduced lateral ventricle activation more in obese than lean participants for the specified food cues.

    Peptide
    Lixisenatide
    Outcome
    DecreaseLateral ventricle functional activation
    Study

    n = 29

    Comparator
    Lean participants with diabetes
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    P value
    < 0.05
    obese vs lean, nonfood vs high-calorie food

    Source sentences

    Summary
    Lixisenatide injection significantly reduced the functional activation of the fusiform gyrus and lateral ventricle in obese individuals with T2DM compared with that in lean individuals with T2DM (nonfood vs. high-calorie food, P<0.05).
    1 context sentence
    Summary · context
    In a randomized, single-blinded, crossover study, 15 lean and 14 obese individuals with T2DM were administered lixisenatide or normal saline subcutaneously with a 1-week washout period.
  3. 03HumanObservational studyMechanism

    In participants with diabetes who ate less after lixisenatide, group-treatment interactions affected activation across reported brain regions for food cues (P<0.05).

    In plain wordsIn participants who ate less after lixisenatide, food-cue brain responses depended on treatment and obesity group.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedBrain activation group-treatment interactions among intake reducers
    Study

    n: not reported in source

    Comparator
    Lean participants with diabetes
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    P value
    < 0.05
    group-by-treatment interaction, caloric-intake reducers

    Source sentences

    Summary
    there were significant interaction effects between group and treatment in the posterior cingulate, medial frontal cortex (high-calorie food vs. low-calorie food, PP<0.05).
    1 context sentence
    Summary · context
    In a randomized, single-blinded, crossover study, 15 lean and 14 obese individuals with T2DM were administered lixisenatide or normal saline subcutaneously with a 1-week washout period.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.